Nature Rev. Cancer 6, 546–558 (2006)
The references cited in Box 1 of this article were incorrect. The corrected box and references are reproduced below. The authors apologize for the error.
References
(ref 151) de Bruijn, M. H., Van der Bliek, A. M., Biedler, J. L. & Borst, P. Differential amplification and disproportionate expression of five genes in three multidrug-resistant Chinese hamster lung cell lines. Mol. Cell. Biol. 6, 4717–4722 (1986).
(ref 152) Kartner, N., Shales, M., Riordan, J. R. & Ling, V. Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res. 43, 4413–4419 (1983).
(ref 153) Ringel, I. & Horwitz, S. B. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J. Natl Cancer Inst. 83, 288–291 (1991).
(ref 154) Ueda, K., Cardarelli, C., Gottesman, M. M. & Pastan, I. Expression of a full-length cDNA for the human “MDR1” gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl Acad. Sci. USA 84, 3004–3008 (1987).
(ref 155) Pastan, I. et al. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc. Natl Acad. Sci. USA 85, 4486–4490 (1988).
(ref 156) Hegedus, T. et al. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim. Biophys. Acta 1587, 318–325 (2002).
(ref 157) Jansen, W. J. et al. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. Br. J. Cancer 77, 359–365 (1998).
(ref 158) Schurr, E., Raymond, M., Bell, J. C. & Gros, P. Characterization of the multidrug resistance protein expressed in cell clones stably transfected with the mouse mdr1 cDNA. Cancer Res. 49, 2729–2733 (1989).
(ref 159) Lothstein, L., Hsu, S. I., Horwitz, S. B. & Greenberger, L. M. Alternate overexpression of two P-glycoprotein [corrected] genes is associated with changes in multidrug resistance in a J774. 2 cell line. J. Biol. Chem. 264, 16054–16058 (1989).
(ref 160) Hendricks, C. B., Rowinsky, E. K., Grochow, L. B., Donehower, R. C. & Kaufmann, S. H. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res. 52, 2268–2278 (1992).
(ref 161) Horton, J. K., Houghton, P. J. & Houghton, J. A. Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard. Cancer Res. 47, 6288–6293 (1987).
(ref 162) Kitazaki, T. et al. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49, 337–343 (2005).
(ref 163) Martin, C. et al. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein. Br. J. Pharmacol. 128, 403–411 (1999).
(ref 164) Wolverton, J. S., Danks, M. K., Schmidt, C. A. & Beck, W. T. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells. Cancer Res. 49, 2422–2426 (1989).
(ref 165) Boesch, D. et al. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res. 51, 4226–4233 (1991).
Additional information
The online version of the original article can be found at 10.1038/nrc1887
Rights and permissions
About this article
Cite this article
Scripture, C., Figg, W. Erratum: Drug interactions in cancer therapy. Nat Rev Cancer 6, 741 (2006). https://doi.org/10.1038/nrc1975
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc1975
This article is cited by
-
B-Cell Depletion Immunotherapy in Pemphigus: Effects on Cellular and Humoral Immune Responses
Journal of Investigative Dermatology (2008)
